About this Journal Submit a Manuscript Table of Contents
Pain Research and Treatment
Volume 2013 (2013), Article ID 898493, 7 pages
http://dx.doi.org/10.1155/2013/898493
Clinical Study

Opioid Use in Fibromyalgia Is Associated with Negative Health Related Measures in a Prospective Cohort Study

1Division of Rheumatology, McGill University, Montreal, QC, Canada H3G 1A4
2Alan Edwards Pain Management Unit, Montreal General Hospital, McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, Canada H3G 1A4
3Faculty of Law, University of Montreal, Montreal, QC, Canada H3C 3J7

Received 9 May 2012; Accepted 18 February 2013

Academic Editor: Muhammad B. Yunus

Copyright © 2013 Mary-Ann Fitzcharles et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Wolfe, D. J. Clauw, M. A. Fitzcharles et al., “The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity,” Arthritis Care and Research, vol. 62, no. 5, pp. 600–610, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. R. M. Bennett, J. Jones, D. C. Turk, I. J. Russell, and L. Matallana, “An internet survey of 2,596 people with fibromyalgia,” BMC Musculoskeletal Disorders, vol. 8, article 27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. M.-A. Fitzcharles, P. A. Ste-Marie, A. Gamsa, M. A. Ware, and Y. Shir, “Opioid use, misuse, and abuse in patients labeled as fibromyalgia,” The American Journal of Medicine, vol. 124, no. 10, pp. 955–960, 2011. View at Publisher · View at Google Scholar
  4. D. L. Goldenberg, K. Ryan, A. Chandran, and G. Zlateva, “What is the true cost of fibromyalgia to our society: results from a cross-sectional survey in the United States,” Arthritis and Rheumatism, vol. 60, supplement 10, p. 104, 2009.
  5. S. Okie, “A flood of opioids, a rising tide of deaths,” The New England Journal of Medicine, vol. 363, no. 21, pp. 1981–1985, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Melzack, “The McGill pain questionnaire: major properties and scoring methods,” PAIN, vol. 1, no. 3, pp. 277–299, 1975. View at Publisher · View at Google Scholar · View at Scopus
  7. C. S. Burckhardt, S. R. Clark, and R. M. Bennett, “The fibromyalgia impact questionnaire: development and validation,” Journal of Rheumatology, vol. 18, no. 5, pp. 728–733, 1991. View at Scopus
  8. J. F. Fries, P. Spitz, R. G. Kraines, and H. R. Holman, “Measurement of patient outcome in arthritis,” Arthritis and Rheumatism, vol. 23, no. 2, pp. 137–145, 1980. View at Scopus
  9. R. F. Meenan, P. M. Gertman, and J. H. Mason, “Measuring health status in arthritis: the arthritis impact measurement scales,” Arthritis and Rheumatism, vol. 23, no. 2, pp. 146–152, 1980. View at Scopus
  10. M. J. L. Sullivan, S. R. Bishop, and J. Pivik, “The pain catastrophizing scale: development and validation,” Psychological Assessment, vol. 7, no. 4, pp. 524–532, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. C. S. Boomershine and L. J. Crofford, “A symptom-based approach to pharmacologic management of fibromyalgia,” Nature reviews Rheumatology, vol. 5, no. 4, pp. 191–199, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. M. Abeles, M. H. Pillinger, B. M. Solitar, and M. Abeles, “Narrative review: the pathophysiology of fibromyalgia,” Annals of Internal Medicine, vol. 146, no. 10, pp. 726–734, 2007. View at Scopus
  13. J. W. Younger, A. J. Zautra, and E. T. Cummins, “Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology,” PLoS ONE, vol. 4, no. 4, Article ID e5180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. E. H. Choy and P. J. Mease, “Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials),” Rheumatic Disease Clinics of North America, vol. 35, no. 2, pp. 329–337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Boulanger, A. J. Clark, P. Squire, E. Cui, and G. L. A. Horbay, “Chronic pain in Canada: have we improved our management of chronic noncancer pain?” Pain Research and Management, vol. 12, no. 1, pp. 39–47, 2007. View at Scopus
  16. A. D. Furlan, J. A. Sandoval, A. Mailis-Gagnon, and E. Tunks, “Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects,” CMAJ: Canadian Medical Association Journal, vol. 174, no. 11, pp. 1589–1594, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. R. M. Bennett, M. Kamin, R. Karim, and N. Rosenthal, “Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study,” The American Journal of Medicine, vol. 114, no. 7, pp. 537–545, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Biasi, S. Manca, S. Manganelli, and R. Marcolongo, “Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo,” International Journal of Clinical Pharmacology Research, vol. 18, no. 1, pp. 13–19, 1998. View at Scopus
  19. W. Häuser, K. Thieme, and D. C. Turk, “Guidelines on the management of fibromyalgia syndrome: a systematic review,” European Journal of Pain, vol. 14, no. 1, pp. 5–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. F. Carville, S. Arendt-Nielsen, H. Bliddal et al., “EULAR evidence-based recommendations for the management of fibromyalgia syndrome,” Annals of the Rheumatic Diseases, vol. 67, no. 4, pp. 536–541, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Burckhardt, D. Goldenberg, L. Crofford, R. Gerwin, S. Gowans, Kackson, et al., “Guideline for the management of fibromyalgia syndrome,” Pain in Adults and Children. APS Clinical Practice Guideline Series 4, American Pain Society, Glenview, Ill, USA, 2005.
  22. G. P. Kurita, P. Sjøgren, K. Juel, J. H. Højsted, and O. Ekholm, “The burden of chronic: a cross-sectional survey focussing on diseases, immigration, and opioid use,” Pain, vol. 153, no. 12, pp. 2332–2338, 2012. View at Publisher · View at Google Scholar
  23. M. Lee, S. Silverman, H. Hansen, V. Patel, and L. Manchikanti, “A comprehensive review of opioid-induced hyperalgesia,” Pain Physician, vol. 14, no. 2, pp. 145–161, 2011. View at Scopus
  24. R. Chou, G. J. Fanciullo, P. G. Fine et al., “Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain,” Journal of Pain, vol. 10, no. 2, pp. 113.e22–130.e22, 2009. View at Publisher · View at Google Scholar
  25. L. J. Crofford, “Adverse effects of chronic opioid therapy for chronic musculoskeletal pain,” Nature Reviews Rheumatology, vol. 6, no. 4, pp. 191–197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. D. M. Hartung, L. Middleton, D. G. Haxby, M. Koder, K. L. Ketchum, and R. Chou, “Rates of adverse events of long-acting opioids in a state medicaid program,” Annals of Pharmacotherapy, vol. 41, no. 6, pp. 921–928, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Manchikanti, B. Fellows, H. Ailinani, and V. Pampati, “Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective,” Pain Physician, vol. 13, no. 5, pp. 401–435, 2010. View at Scopus
  28. A. D. Furlan, R. Reardon, and C. Weppler, “Opioids for chronic noncancer pain: a new Canadian practice guideline,” CMAJ: Canadian Medical Association Journal, vol. 182, no. 9, pp. 923–930, 2010. View at Publisher · View at Google Scholar · View at Scopus